中西医联合治疗对晚期NSCLC miRNA表达谱的影响

发布时间：2018-02-16 22:28

  本文关键词： 晚期非小细胞肺癌 血清miRNA 中西医联合　出处：《中国中西医结合杂志》2016年09期 　论文类型：期刊论文

【摘要】：目的对中西医联合治疗晚期非小细胞肺癌(NSCLC)获益血清miRNA表达谱进行初步研究,探讨晚期NSCLC疗效监测和预测分子标记物。方法选取5例接受中西医联合治疗且疗效获益的晚期NSCLC患者(简称治疗组)和3例晚期NSCLC初治患者(简称肺癌组)及3名健康体检者(简称对照组),采集血清标本并用Trizol法提取总RNA,运用Exiqon公司microRNA PCR ARRAY芯片技术筛选检测肺癌组血清与对照组血清中差异miRNA表达谱、治疗组血清与肺癌组血清差异miRNA表达谱,基于聚类分析及对比分析,进一步得到中西医联合治疗晚期NSCLC获益miRNA表达谱。结果经microRNA PCR ARRAY检测和数据分析处理后,肺癌组与对照组共筛选出42个差异在2倍以上的miRNAs,其中29个为上调的miRNAs,13个为下调的miRNAs;且miR-10b-5p、miR-21-5p、miR-182-5p、miR-361-3p、miR-382-5p差异有统计学意义(P0.05)。治疗组与肺癌组筛选出45个差异在2倍以上的miRNAs,其中12个上调的miRNAs,33个下调的miRNAs;miR-137-3p、miR-182-5p、miR-376a-3p、miR-382-5p、miR-409-3p、miR-10a-5p、miR-21-5p、miR-29a-3p、miR-141-3p、miR-150-5p、miR-200c-3p、miR-342-3p、miR-365a-3p、miR-375、miR-502-3p 15个miRNAs差异有统计学意义(P0.05)。治疗组与肺癌组差异倍数2倍,与对照组差异倍数≤2倍的血清miRNA共筛选出22个,其中7个为上调miRNAs,15个为下调miRNAs;miR-127-3p、miR-182-5p、miR-382-5p、miR-409-3p、miR-10a-5p、miR-21-5p、miR-141-3p、miR-342-3p 8个miRNAs差异有统计学意义(P0.05)。结论包括miR-21-5p、miR-182-5p、miR-382-5p在内的差异miRNAs有望成为中西医联合治疗晚期NSCLC疗效监测和预测分子标记物;为中西医联合治疗晚期NSCLC个体化治疗提供参考。
[Abstract]:Objective to study the expression profile of serum miRNA in patients with advanced non-small cell lung cancer (NSCLC) treated with combination of traditional Chinese and western medicine. To explore the molecular markers for monitoring and predicting the efficacy of advanced NSCLC. Methods five patients with advanced NSCLC who received combined traditional Chinese and Western medicine therapy and three patients with advanced NSCLC were selected as control group and 3 patients with lung cancer. Serum samples were collected from healthy controls and total RNAs were extracted by Trizol method. The differential miRNA expression profiles in serum of lung cancer group and control group were detected by microRNA PCR ARRAY chip technique of Exiqon company. The differential miRNA expression profile in serum of treatment group and lung cancer group was further obtained based on cluster analysis and comparative analysis. Results after microRNA PCR ARRAY detection and data analysis, the miRNA expression profile of NSCLC was obtained in the late stage of treatment with combination of traditional Chinese and western medicine. A total of 42 miRNAss of lung cancer group and control group were screened out, of which 29 were upregulated miRNAss and 13 were down-regulated miRNAss, and there were significant differences in miR-182-5ptimiR-361-3ptimiR-382-5P between the treatment group and the lung cancer group, and 45 miRNAss with a difference of more than 2 times were screened between the treatment group and the lung cancer group. Twelve of the upregulated miRNAss, and 33 down-regulated miR-137-3phe miR-182-5 pnmiR-376a-3pnmiR-382-5pmiR-409-3 pnmiR-10a-5pnmiR-29a-3pmiR-141-3pmiR-150-5pmiR-3pmiR-342-3pmiR-365a-3pnmiR-375miR-502-3p, have statistical significance. The difference between the treatment group and the lung cancer group is 2 times higher than that of the lung cancer group, and the difference between the treatment group and the lung cancer group is 2 times higher than that of the control group. A total of 22 serum miRNA with a difference of 鈮，

本文编号：1516578